1h Free Analyst Time
Intercellular Adhesion Molecule 1 - Pipeline Review, H2 2019Speak directly to the analyst to clarify any post sales queries you may have.
Summary
Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Intercellular Adhesion Molecule 1 (ICAM-1) is a protein encoded by the ICAM1 gene. It acts as a receptor for major receptor group rhinovirus A-B capsid proteins and Coxsackievirus A21 capsid proteins. ICAM1 promotes the assembly of endothelial apical cups through ARHGEF26/SGEF and RHOG activation.
Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 1, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Immunology, Central Nervous System, Genito Urinary System And Sex Hormones and Ophthalmology which include indications Anaplastic Thyroid Cancer, Cholangitis, Crohn's Disease (Regional Enteritis), Hepatocellular Carcinoma, Inflammation, Kidney Fibrosis, Liver Fibrosis, Multiple Sclerosis, Pancreatic Islet Transplant Rejection, Pouchitis, Refractory Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis and Ulcerative Colitis.
The latest report Intercellular Adhesion Molecule 1 Pipeline Review, H2 2019, outlays comprehensive information on the Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1)
- The report reviews Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
IntroductionReport Coverage
Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Overview
Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Companies Involved in Therapeutics Development
Atlantic Healthcare Plc
China Medical System Holdings Ltd
Phio Pharmaceuticals Corp
Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Drug Profiles
alicaforsen sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotide to Inhibit ICAM-1 for Oncology and Retinal Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMS-024 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNP-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target ICAM-1 for Anaplastic Thyroid Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melittin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MS-553 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Dormant Products
Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Discontinued Products
Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Product Development Milestones
Featured News & Press Releases
Jul 31, 2019: Atlantic Healthcare announces results from Phase 3 Trial of Alicaforsen Enema for Orphan-Designated Pouchitis
May 01, 2019: Atlantic Healthcare to attend Digestive Diseases Week in San Diego, May 18-21
Nov 12, 2018: Atlantic Healthcare to present a poster at the Crohns & Colitis Foundation IBD: Innovate conference in New York on Tuesday, November 13, 2018
Nov 12, 2018: Atlantic Healthcare to present at the Stifel 2018 Healthcare Conference in New York
Sep 27, 2018: Atlantic Healthcare reports results from Phase 1 trial of tablet for Crohn’s
Sep 13, 2018: Atlantic Healthcare secures acceptance of brand name Camligo for alicaforsen enema to treat pouchitis
Aug 02, 2018: Strategic appointment expands Atlantic Healthcare executive team
May 02, 2018: Atlantic Healthcare completes patient enrollment to its Phase 3 study of alicaforsen to treat IBD Pouchitis
Jan 08, 2018: Atlantic Healthcare is attending the JP Morgan Healthcare Conference and the Crohn's and Colitis Congress
Nov 08, 2017: Atlantic Healthcare to present at the Stifel 2017 Healthcare Conference in New York on November 15, 2017
May 30, 2017: Atlantic Healthcare develops tablet formulations of alicaforsen to treat Crohn's disease and Ulcerative Colitis
May 22, 2017: Atlantic Healthcare announces strengthening of the Board as it prepares for commercialisation of alicaforsen in its first indication
May 01, 2017: Atlantic Healthcare initiates FDA rolling submission of its New Drug Application for alicaforsen in the treatment of pouchitis
Apr 24, 2017: Atlantic Healthcare appoints Durbin as Nordic regions distributor of alicaforsen under the Named Patient Programme
Apr 02, 2017: Cell therapy provides shot at a cure for fatal thyroid cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Atlantic Healthcare Plc, H2 2019
Pipeline by China Medical System Holdings Ltd, H2 2019
Pipeline by Phio Pharmaceuticals Corp, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Atlantic Healthcare Plc
- China Medical System Holdings Ltd
- Phio Pharmaceuticals Corp
